ArticleFrontiers in immunology2021
Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis.Infectious diseases of poverty · 2023Pooled it
- COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19.International journal of molecular sciences · 2022Pooled it
- Associations between Serum Interleukins (IL-1BioMed research international · 2022Pooled it
- Article
- Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells.BMC cardiovascular disorders · 2025Article
- Using virtual patient cohorts to uncover immune response differences in cancer and immunosuppressed COVID-19 patients.PLoS computational biology · 2025Article
- Mitochondrial dysfunction in acute and post-acute phases of COVID-19 and risk of non-communicable diseases.npj metabolic health and disease · 2024Review
- Interleukin 6 Antagonists in Severe COVID-19 Disease: Cardiovascular and Respiratory Outcomes.Protein and peptide letters · 2024Review
- Development of a prediction nomogram for IgG levels among asymptomatic or mild patients with COVID-19.Frontiers in cellular and infection microbiology · 2024Article
- Influence of polymorphic variations of IFNL, HLA, and IL-6 genes in severe cases of COVID-19.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Analysis of cytokine levels, cytological findings, and MP-DNA level in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia.Immunity, inflammation and disease · 2023Article
- Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19.International journal of molecular sciences · 2023Article
- Polymorphisms in theFrontiers in immunology · 2023Article
- Article
- Machine Learning Approaches to Analyze MALDI-TOF Mass Spectrometry Protein Profiles.Methods in molecular biology (Clifton, N.J.) · 2022Article
- A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19.Pharmaceutics · 2021Review
- Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19.Inflammopharmacology · 2021Review
- Article
- Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?medRxiv : the preprint server for health sciences · 2021Article
- One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? - The Summarising Review.International journal of public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comprehensive understanding of the dynamic changes in interleukin-6 (IL-6) levels is essential for monitoring and treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). By analyzing the correlations between IL-6 levels and health conditions, underlying diseases, several key laboratory detection indices, and the prognosis of 1,473 patients with the coronavirus disease 2019 (COVID-19), the role of IL-6 during SARS-CoV-2 infection was demonstrated. Our results indicated that IL-6 levels were closely related to age, sex, body temperature, oxygen saturation (SpO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.